FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer
Written by
Cancer Network
Published
0
comments
0
min
Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.